Peer-reviewed veterinary case report
Masitinib treatment results in partial or complete remission in some
By Holtermann, N et al.·Published in Veterinary and comparative oncology·2016·Ludwig Maximilians University Munich, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Masitinib monotherapy in canine epitheliotropic lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with a type of skin cancer called epitheliotropic lymphoma were treated with a medication called masitinib. Out of 10 dogs, 2 achieved complete remission for about 85 days, while 5 had partial remission lasting around 60 days. Some dogs experienced mild to moderate side effects, but overall, masitinib showed effectiveness in treating this condition. The study suggests that the treatment works through different mechanisms rather than the KIT receptor, which is often involved in other cancers.
People also search for: dog skin cancer treatment · masitinib for canine lymphoma · dog lymphoma remission rates
Abstract
This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26364581/